When Clinical Supply Fails, Small Biotech Trials Stall

By Khaled El-Gendy, founder, Pathway Strategy Partners

Small biotech companies rarely struggle because their science lacks promise. More often, they face pressure where science meets execution. Among the most underestimated of these pressure points is clinical supply.

For small studies, particularly those extending across several countries, clinical supply is not just a logistics activity. It is a strategic function. If the right material is not available at the right site, under the right conditions, with the right documentation, the study does not move. Patients cannot be dosed, timelines slip, sites lose confidence, and valuable cash runway starts to erode.

Large pharmaceutical companies often have the advantage of established infrastructure, mature vendor networks, and internal teams dedicated to managing global complexity. Small biotechs operate differently. They work with lean structures, limited capital, and little room for operational error. That is exactly why clinical supply planning must be sharper, earlier, and more disciplined.

For small biotech studies, securing global clinical supplies is not about moving product from one location to another. It is about protecting the study itself.

Start Supply Strategy Early

One of the most common mistakes in emerging biotech is treating clinical supply as something to address only after the protocol is finalized. In reality, supply strategy should begin in parallel with study design.

The protocol drives supply complexity. Trial geography, patient population, treatment schedule, randomization, comparator requirements, temperature controls, dose presentation, and enrollment assumptions all influence the supply model. A study that looks manageable at a high level can become operationally fragile once it involves multiple countries, cold chain products, blinded packaging, short shelf life, or uncertain recruitment.

That is why small biotech teams should ask a more strategic question at the outset: not merely “How do we get product to sites?” but “What supply model gives this study the highest probability of uninterrupted execution without creating avoidable cost or risk?”

That discussion should involve clinical operations, clinical supply, quality, regulatory, and finance. Even if a small company does not have all of those functions in-house, those perspectives still need to be represented through experienced external support. Supply failures rarely begin with a late shipment. More often, they begin with weak assumptions upstream.

Forecasting Must Be Realistic

Forecasting is one of the most sensitive parts of supply planning for small biotech studies. Early assumptions are often more optimistic than operational reality. Teams may expect fast site activation, smooth country approvals, or stronger than likely recruitment. In practice, enrollment patterns vary by country, timelines shift, and some activated sites may recruit little or not at all.

This creates two expensive risks: undersupply and oversupply.

Undersupply can lead to emergency shipments, treatment interruption, and avoidable pressure on sites. Oversupply ties up working capital in inventory that may expire before use. For a small biotech company, both can be damaging.

The answer is not simply more stock. It is a more disciplined forecasting model built around scenarios, not hope. At minimum, companies should plan against a base case, an accelerated enrollment case, and a delayed recruitment case. They should understand their lead times, resupply triggers, buffer requirements, and expiry exposure by region.

A forecast should be treated as a living operational tool, updated continuously as actual site performance and enrollment data become available. In smaller studies, where every shipment and every patient matter, this level of discipline can directly influence both budget and timeline.

Comparator Sourcing Is Often The Hidden Challenge

In many studies, comparator sourcing is where supply complexity increases sharply. Whether the protocol includes an active comparator, rescue medication, or supportive care product, securing those supplies globally can be far more difficult than many teams anticipate.

Availability is only part of the challenge. There are also questions of authenticity, traceability, shelf life, batch consistency, local presentation, and regulatory acceptability. The same medicine may be available in different strengths, artworks, languages, or pack formats across markets. A product that is commercially obtainable in one country may create packaging, blinding, or compliance complications in another.

Small biotech companies need to approach comparator sourcing strategically and early. They need qualified sourcing channels, strong documentation, and a clear decision on whether sourcing will be centralized or regionalized. They also need to understand whether the product will require relabeling, repackaging, blinding, import permits, or additional quality review before it can be used in the study.

When a comparator is in intermittent shortage or available only through limited channels, delay in sourcing can delay the entire trial. That is why comparator planning should be treated as a central part of study feasibility, not as a last-minute procurement exercise.

Global Trials Require Local Realism

A common misconception in multinational studies is the assumption that one supply model can be applied identically across all countries. Small biotechs are especially vulnerable to this thinking because simplicity feels cost-effective. In practice, global trials rarely work that way.

Each country brings its own operational reality. Import licensing, customs timelines, local language requirements, depot capabilities, documentation standards, release expectations, and cold chain infrastructure can differ substantially. Even within the same region, these differences can affect study start-up and continuity.

Successful global supply therefore depends on standardization where possible and localization where necessary.

A biotech company should have one overall supply strategy, one governance framework, and one central view of inventory and risk. But country-level execution may still need to differ. Some countries may support central depot supply. Others may require local storage, specialized customs handling, or different release workflows. Ignoring these realities in pursuit of simplicity usually creates bigger delays later.

For small studies, practical local knowledge is not a luxury. It is an operational necessity.

Quality Oversight Is Part Of Supply Security

When budgets are tight, there can be a temptation to prioritize speed and treat quality systems as secondary. In clinical supply, that is a dangerous trade-off.

A supply chain is only secure when it is controlled. That means visibility over release status, labeling, storage conditions, shipment monitoring, chain of custody, deviations, reconciliation, and destruction procedures. It also means strong oversight of packaging vendors, freight providers, depots, and comparator sources.

This does not require excessive bureaucracy. Small biotechs do not need large structures to maintain control. But they do need clear responsibilities, qualified vendors, reliable documentation, and rapid escalation when issues arise. A shipment arriving late is one problem. A shipment arriving with unclear temperature history or incomplete documentation is a much bigger one.

Quality and continuity are inseparable. Weak oversight may remain hidden for weeks, then suddenly surface as a site complaint, a deviation, or a costly study delay.

Resilience Matters As Much As Efficiency

Small biotech companies are right to watch cost carefully. But the cheapest-looking supply plan is not always the most economical one.

A model with no meaningful buffer stock, no alternative route, no secondary sourcing option, and no contingency for customs delay may appear efficient on paper. In execution, it can become highly expensive as soon as something goes wrong. And in global clinical studies, disruptions do occur.

Resilience should therefore be built selectively into the supply model. This may include strategic buffer stock for key markets, alternative transportation lanes, backup comparator sources where possible, or packaging strategies that reduce complexity across countries. The objective is not excess. The objective is protection.

A useful test for any small biotech team is simple: if one part of the supply chain fails next month, can enrolled patients continue treatment without interruption? If the answer is no, that risk deserves action now.

The Right Partners Extend Capability

Most small biotech companies rely heavily on external partners for packaging, labeling, comparator sourcing, storage, transportation, and regional regulatory support. But outsourcing activity is not the same as outsourcing accountability.

The strongest partners do more than execute tasks. They identify risk early, communicate clearly, challenge unrealistic assumptions, and respond with urgency. They understand that even a modest delay can have outsized consequences for a small biotech company operating against funding milestones and investor expectations.

That is why partner selection should not be based on price alone. Relevant study experience, comparator expertise, geographic capability, responsiveness, transparency, and quality maturity all matter. For a lean biotech organization, the right partner can significantly expand operational capability. The wrong one can multiply risk.

Final Thought

Securing global clinical supplies for small biotech studies is ultimately about ensuring that promising science is not undermined by preventable operational weakness.

The companies that succeed are not always the biggest or best funded. They are the ones that plan early, forecast realistically, manage comparator risk carefully, respect country-level realities, maintain quality discipline, and build resilience into the points of greatest vulnerability.

In small biotech, continuity is everything. When supply is secure, patients remain on treatment, sites remain confident, timelines remain credible, and the study keeps moving forward.

That is not merely logistics. It is executional advantage.

About The Author:

Khaled El-Gendy is a senior pharmaceutical and clinical trials executive with more than 25 years of international experience across clinical supply chain, comparator drug sourcing, and strategic business development. He has supported biotech, pharmaceutical, and service organizations in navigating complex global markets, securing critical trial supplies, and building high-value commercial partnerships. He is the founder of Pathway Strategy Partners, a UAE-based advisory firm focused on life sciences, market access, and growth strategy.